Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| Market is closed on Tue. Jul. 14, 2020 | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 0% (three month average) | | RSI | | | Latest Price | $(0%) | | Stocks Behave Similarly | Similar Stock List | | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability)
UNG(58%) IBUY(32%) ARKG(34%) ARKK(26%) XBI(27%) | | Factors Impacting VBIV price | VBIV will advance at least -0% in a week (0% probabilities).
ACES(-20%) VWO(-26%) EEM(-24%) IBB(-11%) SIL(16%) | | | | | | | | Relative Volatility | | | | | | Market Trend Strength | 0% (StdDev 0%) | | Hourly BBV | 0 () | | Intraday Trend | NAN% | | | | | |
|
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA. VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |